DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

Information source: Hartford Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cystic Fibrosis; Pneumonia; Pseudomonas Aeruginosa Infection

Intervention: meropenem (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Joseph Kuti

Official(s) and/or principal investigator(s):
Joseph L Kuti, Pharm.D., Principal Investigator, Affiliation: Hartford Hospital


This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation. Safety and practicality of administering meropenem as a 3 hour infusion will be measured.

Clinical Details

Official title: An Open Label Study to Assess the Population Pharmacokinetics, Safety, and Practicality of Administering Meropenem as a Prolonged Infusion to Cystic Fibrosis Children Admitted With an Acute Pulmonary Exacerbation

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Population Pharmacokinetics - Total Body Clearance

Population Pharmacokinetics - Volume of Central Compartment

Secondary outcome:


Practicality of 3 Hour Prolonged Infusion

Meropenem Pharmacodynamics

Detailed description: This study will be conducted at 7 pediatric hospitals in the United States (Columbia University Medical Center, New York, New York; University of North Carolina, Chapel Hill, North Carolina; St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, Connecticut Children's Medical Center, Hartford, Connecticut, Riley Hospital for Children, Indianapolis, Indiana, Nationwide Hospital for Children, Columbus, Ohio, and Children's Medical Center, Dallas, Texas). Cystic Fibrosis children (age 6-17 years) admitted to one of these enrolling sites with an acute exacerbation of his or her pulmonary infection who require antibiotic therapy with meropenem will be eligible. Meropenem will be administered as a 3 hour prolonged infusion and blood concentrations will be measured to determine the population pharmacokinetics in 30 patients, the safety of prolonged infusion meropenem, and the practicality as measured be treatment burden using a questionaire. The population pharmacokinetic model developed will be utilized to determine the optimal dose of meropenem to administer to children with Cystic Fibrosis, and define an exposure response relationship for the drug in this population.


Minimum age: 6 Years. Maximum age: 17 Years. Gender(s): Both.


Inclusion Criteria:

- Cystic Fibrosis

- Hospitalized with acute pulmonary exacerbation

- Caused by Pseudomonas aeruginosa or other bacteria against which meropenem would be

an appropriate antibiotic treatment Exclusion Criteria:

- Known allergy to meropenem

- Require less than 3 days of meropenem in the hospital

- Require another systemic Beta-lactam antibiotic to treat a concomitant pathogen

- Known fungal or viral infection

- Females in their 2nd or 3rd trimester of pregnancy

- Moderate to severe renal dysfunction, as defined by a creatinine clearance less than

50 ml/min/1. 73m2 (by use of Schwartz method)

- History of solid organ transplantation within previous 6 months

- Active or recent (within 30 days) participation in another antibiotic clinical trial

Locations and Contacts

Connecticut Children's Medical Center, Hartford, Connecticut 06106, United States

Riley Hospital for Children, Indianapolis, Indiana 46202, United States

Columbia University Medical Center Children's Hospital, New York, New York 10032, United States

University of North Carolina, North Carolina Children's Hospital, Chapel Hill, North Carolina 27514, United States

Nationwide Children's Hospital, Colubmus, Ohio 43205, United States

St. Christopher's Hospital for Children, Philadelphia, Pennsylvania 19134, United States

Children's Medical Center, Dallas, Texas 75235, United States

Additional Information

Starting date: February 2012
Last updated: March 26, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017